Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis

D. Landi; S. Vollaro; G. Pellegrino; D. Mulas; Delia Mulas; A. Ghazaryan; E. Falato; P. Pasqualetti; Patrizio Pasqualetti; P. M. Rossini; Paolo Maria Rossini; M. M. Filippi

doi:10.1016/j.clinph.2014.05.031

Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis

D. Landi, S. Vollaro, G. Pellegrino, D. Mulas, Delia Mulas, A. Ghazaryan, E. Falato, P. Pasqualetti, Patrizio Pasqualetti, P. M. Rossini, Paolo Maria Rossini, M. M. Filippi

Università Cattolica del Sacro Cuore

Risultato della ricerca: Contributo in rivista › Articolo in rivista

22 Citazioni (Scopus)

Abstract

Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5mg/day.

Lingua originale	English
pagine (da-a)	165-169
Numero di pagine	5
Rivista	Clinical Neurophysiology
Volume	126
DOI	https://doi.org/10.1016/j.clinph.2014.05.031
Stato di pubblicazione	Pubblicato - 2015

Keywords

Administration, Oral
Adult
Animals
Evoked Potentials, Motor
Female
Fingolimod
Fingolimod Hydrochloride
Glutamate
Glutamic Acid
Humans
Immunosuppressive Agents
Intracortical facilitation
Male
Middle Aged
Motor Cortex
Motor cortex
Multiple Sclerosis, Relapsing-Remitting
Multiple sclerosis
Propylene Glycols
Prospective Studies
Sphingosine
Transcranial Magnetic Stimulation
Transcranial magnetic stimulation

Accesso al documento

10.1016/j.clinph.2014.05.031

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Landi, D., Vollaro, S., Pellegrino, G., Mulas, D., Mulas, D., Ghazaryan, A., Falato, E., Pasqualetti, P., Pasqualetti, P., Rossini, P. M., Rossini, P. M., & Filippi, M. M. (2015). Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis. Clinical Neurophysiology, 126, 165-169. https://doi.org/10.1016/j.clinph.2014.05.031

@article{a38a1fe0806f4b55a9eb5572a152db9c,

title = "Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis",

abstract = "Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5mg/day.",

keywords = "Administration, Oral, Adult, Animals, Evoked Potentials, Motor, Female, Fingolimod, Fingolimod Hydrochloride, Glutamate, Glutamic Acid, Humans, Immunosuppressive Agents, Intracortical facilitation, Male, Middle Aged, Motor Cortex, Motor cortex, Multiple Sclerosis, Relapsing-Remitting, Multiple sclerosis, Propylene Glycols, Prospective Studies, Sphingosine, Transcranial Magnetic Stimulation, Transcranial magnetic stimulation, Administration, Oral, Adult, Animals, Evoked Potentials, Motor, Female, Fingolimod, Fingolimod Hydrochloride, Glutamate, Glutamic Acid, Humans, Immunosuppressive Agents, Intracortical facilitation, Male, Middle Aged, Motor Cortex, Motor cortex, Multiple Sclerosis, Relapsing-Remitting, Multiple sclerosis, Propylene Glycols, Prospective Studies, Sphingosine, Transcranial Magnetic Stimulation, Transcranial magnetic stimulation",

author = "D. Landi and S. Vollaro and G. Pellegrino and D. Mulas and Delia Mulas and A. Ghazaryan and E. Falato and P. Pasqualetti and Patrizio Pasqualetti and Rossini, {P. M.} and Rossini, {Paolo Maria} and Filippi, {M. M.}",

year = "2015",

doi = "10.1016/j.clinph.2014.05.031",

language = "English",

volume = "126",

pages = "165--169",

journal = "Clinical Neurophysiology",

issn = "1872-8952",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis

AU - Landi, D.

AU - Vollaro, S.

AU - Pellegrino, G.

AU - Mulas, D.

AU - Mulas, Delia

AU - Ghazaryan, A.

AU - Falato, E.

AU - Pasqualetti, P.

AU - Pasqualetti, Patrizio

AU - Rossini, P. M.

AU - Rossini, Paolo Maria

AU - Filippi, M. M.

PY - 2015

Y1 - 2015

N2 - Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5mg/day.

AB - Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5mg/day.

KW - Administration, Oral

KW - Adult

KW - Animals

KW - Evoked Potentials, Motor

KW - Female

KW - Fingolimod

KW - Fingolimod Hydrochloride

KW - Glutamate

KW - Glutamic Acid

KW - Humans

KW - Immunosuppressive Agents

KW - Intracortical facilitation

KW - Male

KW - Middle Aged

KW - Motor Cortex

KW - Motor cortex

KW - Multiple Sclerosis, Relapsing-Remitting

KW - Multiple sclerosis

KW - Propylene Glycols

KW - Prospective Studies

KW - Sphingosine

KW - Transcranial Magnetic Stimulation

KW - Transcranial magnetic stimulation

KW - Administration, Oral

KW - Adult

KW - Animals

KW - Evoked Potentials, Motor

KW - Female

KW - Fingolimod

KW - Fingolimod Hydrochloride

KW - Glutamate

KW - Glutamic Acid

KW - Humans

KW - Immunosuppressive Agents

KW - Intracortical facilitation

KW - Male

KW - Middle Aged

KW - Motor Cortex

KW - Motor cortex

KW - Multiple Sclerosis, Relapsing-Remitting

KW - Multiple sclerosis

KW - Propylene Glycols

KW - Prospective Studies

KW - Sphingosine

KW - Transcranial Magnetic Stimulation

KW - Transcranial magnetic stimulation

UR - http://hdl.handle.net/10807/69801

U2 - 10.1016/j.clinph.2014.05.031

DO - 10.1016/j.clinph.2014.05.031

M3 - Article

SN - 1872-8952

VL - 126

SP - 165

EP - 169

JO - Clinical Neurophysiology

JF - Clinical Neurophysiology

ER -

Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo